What does the brentuximab vedotin prescribing information recommend about breastfeeding during treatment?

For brentuximab vedotin, decide whether to discontinue breastfeeding or discontinue/abstain from therapy, weighing potential breastfeeding risk to the child against therapy benefit for the woman, since human milk excretion of the drug or its metabolites is unknown and infant risk cannot be excluded.